TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.
about
Ceramide synthases at the centre of sphingolipid metabolism and biologyAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraOnto better TRAILs for cancer treatmentCaspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell linesAcute myeloid leukemia-targeted toxin activates both apoptotic and necroptotic death mechanismsProtein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancerTRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitroNovel Structurally Related Flavones Augment Cell Death Induced by rhsTRAILBortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways5-allyl-7-gen-difluoromethoxychrysin enhances TRAIL-induced apoptosis in human lung carcinoma A549 cellsCytotoxic and immune-sensitizing properties of nitric oxide-modified Saquinavir in iNOS-positive human melanoma cells.Genotyping the GALNT14 gene by joint analysis of two linked single nucleotide polymorphisms using liver tissues for clinical and geographical comparisonsDiet and lifestyle factors modify immune/inflammation response genes to alter breast cancer risk and prognosis: the Breast Cancer Health Disparities Study.ROS and CHOP are critical for dibenzylideneacetone to sensitize tumor cells to TRAIL through induction of death receptors and downregulation of cell survival proteins.Lung cancer therapeutics that target signaling pathways: an update.Chalcones enhance TRAIL-induced apoptosis in prostate cancer cells.Dietary chalcones with chemopreventive and chemotherapeutic potential.Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs.A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase.Chestnut extract induces apoptosis in AGS human gastric cancer cells.Effect of ALA-mediated photodynamic therapy in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on bladder cancer cellsEnhancing apoptosis in TRAIL-resistant cancer cells using fundamental response rulesInduction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA.Inhibition of never in mitosis A (NIMA)-related kinase-4 reduces survivin expression and sensitizes cancer cells to TRAIL-induced cell death.Mitochondrial inhibitor sensitizes non-small-cell lung carcinoma cells to TRAIL-induced apoptosis by reactive oxygen species and Bcl-X(L)/p53-mediated amplification mechanisms.5,7-Dihydroxyflavone Enhances the Apoptosis-Inducing Potential of TRAIL in Human Tumor Cells via Regulation of Apoptosis-Related ProteinsCarbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma.EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins.Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.Expression profile of SIX family members correlates with clinic-pathological features and prognosis of breast cancer: A systematic review and meta-analysis.EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?Targeting Six1 by lentivirus-mediated RNA interference inhibits colorectal cancer cell growth and invasion.P2X7-mediated chemoprevention of epithelial cancers.Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy.P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway.Towards novel paradigms for cancer therapy.Resistance to TRAIL and how to surmount it.Targeting microRNAs to modulate TRAIL-induced apoptosis of cancer cells.An update on antitumor activity of naturally occurring chalcones.
P2860
Q24609859-22673FA6-A860-47DB-AE79-E51B6C790BB7Q26751344-B2D3CD56-8649-47B7-9D14-797B8546E455Q26768160-F279D077-F306-4B57-8D09-E716749B1D1DQ30398758-CA91CC06-D6E6-49D5-A6FF-714C8836E77CQ33392660-9A9124B0-BE98-4A52-9E2D-022744DE99C3Q33569854-EB5F6609-3131-413D-B145-43FF11B1FD64Q33658593-D06B3AE3-D237-4C61-A978-F0B546744FF2Q33802751-8BDB12A7-6801-4762-A281-69D2F3559360Q33838733-48D94A30-014E-4598-AA0F-E54D4568144FQ33907593-335B48FD-23C5-4061-9CF1-3E8C8488536FQ33975484-CF6B6A0F-2B02-48F0-9F34-BB8A90557B4BQ34179539-1E0841D2-C303-4468-A7B9-91F20DC9D1B3Q34293256-5EC9FEC6-6CCE-4B2D-B939-01A049DD57CDQ34359953-5E13CEED-0424-4FE1-96F5-7B63AA4BE3BCQ34496536-E0B0067F-51C7-4241-94E2-701C14452E52Q34541960-E65BD510-39B9-4200-B01B-CDA173D7C330Q34616831-D7147108-07C9-47CD-BD2C-8B9A05001E7CQ34975832-DA17852C-B7CB-43D0-A263-4033E655772CQ35032216-6B77A781-0FDA-4E61-8BA0-FDF29C99A558Q35038107-F3C8FF7D-D395-4648-9CFC-FC6447704D50Q35097709-3CC1B9A1-AACB-4D15-8327-CA2B6B64ADE1Q35104391-B74E578D-12EF-491A-8C66-9C9478E45A50Q35551640-4FF9F6C4-19CB-4965-8BCF-47E9C2E0EA1DQ36070101-BD38DF7C-4F34-473E-9325-822110C49649Q36125103-983112A8-A400-4B9A-9EA6-A7E1EADFFF2EQ36292039-23875B27-442E-43CB-A2D9-F5C7DF95E0C9Q36692259-69424F97-DC5C-4752-8FC6-53AFAAB52B15Q36936884-89B73DD3-6462-4B84-8BCD-C1E06E984655Q37262805-0F7AECB0-2B00-475C-ADD7-F37FE6D4B59DQ37299291-B0812F22-9E0B-41AA-ABE7-66367640ECBCQ37328021-A95DC404-B31A-4648-AD25-FF5FA55655C1Q37561771-DD54402A-35A2-4750-A83C-38B25C69CDD3Q37587365-7CC1B59E-D846-4122-A337-2BA379CC152BQ37618815-1ED79EF7-864F-4648-8D6F-5705BA7B4F60Q37621564-7AECE9B8-A025-4DFE-BA3B-6CA5B80C8FDFQ37723845-58B4B686-DD1F-4C3F-B5A9-BF73525627F7Q37799251-DAAEE4A6-A7A2-491F-825F-F014F8598B2CQ37992546-AC981087-3B84-4CDB-B460-532A4EF6A415Q38058733-215E7079-1850-4287-AAF8-27BD2AD01C3AQ38108304-E69892D7-B268-433D-A166-43FDA2C8A8FA
P2860
TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.
@ast
TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.
@en
type
label
TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.
@ast
TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.
@en
prefLabel
TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.
@ast
TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.
@en
P2860
P1476
TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them
@en
P2093
Andrew Thorburn
Heide Ford
P2860
P356
10.1016/J.DRUP.2008.02.001
P577
2008-02-01T00:00:00Z